65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC

CCRT followed by D consolidation is the standard of care (SOC) for patients (pts) with unresectable stg III NSCLC; however, more than half of pts still have disease progression and die within 5 years. Dual IO with PD-(L)1 and CTLA-4 inhibitors has shown durable benefit in pts with metastatic NSCLC and may improve antitumor control as consolidation after CCRT in pts with unresectable stg III NSCLC. Here, we report final results from CheckMate 73L, a phase 3 study comparing N + CCRT followed by consolidation N + I or N v CCRT followed by D in this pt population.